Abstract
GLP-1R agonists improve outcomes in ischemic heart disease. Here we studied GLP-1R-dependent adaptive and cardioprotective responses to ventricular injury. Glp1r-/- hearts exhibited chamber-specific differences in gene expression, but normal mortality and left ventricular (LV) remodeling after myocardial infarction (MI) or experimental doxorubicin-induced cardiomyopathy. Selective disruption of the cardiomyocyte GLP-1R in Glp1rCM-/- mice produced no differences in survival or LV remodeling following LAD coronary artery occlusion. Unexpectedly, the GLP-1R agonist liraglutide still produced robust cardioprotection and increased survival in Glp1rCM-/- mice following LAD coronary artery occlusion. Although liraglutide increased heart rate (HR) in Glp1rCM-/- mice, basal HR was significantly lower in Glp1rCM-/- mice. Hence, endogenous cardiomyocyte GLP-1R activity is not required for adaptive responses to ischemic or cardiomyopathic injury, and is dispensable for GLP-1R agonist-induced cardioprotection or enhanced chronotropic activity. However the cardiomyocyte GLP-1R is essential for the control of HR in mice.
Original language | English |
---|---|
Pages (from-to) | 507-517 |
Number of pages | 11 |
Journal | Molecular Metabolism |
Volume | 3 |
Issue number | 5 |
DOIs | |
State | Published - Aug 2014 |
Keywords
- Cardiomyopathy
- Glucagon-like peptide-1
- Glucagon-like peptide-1 receptor
- Heart failure
- Incretin
- Ischemia
- Myocardial infarction